Trials / Recruiting
RecruitingNCT07223125
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-89862175 | JNJ-89862175 will be administered. |
Timeline
- Start date
- 2025-10-10
- Primary completion
- 2026-12-15
- Completion
- 2028-08-15
- First posted
- 2025-10-31
- Last updated
- 2026-04-13
Locations
6 sites across 3 countries: United States, France, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07223125. Inclusion in this directory is not an endorsement.